Experienced in Melanoma

Dr. Rodney P. Rocconi

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
State Of Mississippi - University Of Mississippi Medical Center
350 W Woodrow Wilson Dr, Cancer Institute, 
Jackson, MS 
Accepting New Patients
Offers Telehealth
Experienced in Melanoma
State Of Mississippi - University Of Mississippi Medical Center
350 W Woodrow Wilson Dr, Cancer Institute, 
Jackson, MS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rodney Rocconi is a Gynecologic Oncologist and an Oncologist in Jackson, Mississippi. Dr. Rocconi is rated as an Experienced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Cervical Cancer, and Hysterectomy. Dr. Rocconi is currently accepting new patients.

His clinical research consists of co-authoring 79 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 2 clinical trials in the study of Melanoma.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in AL
Hospital Affiliations
University Of Mississippi Med Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

STATE OF MISSISSIPPI - UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
350 W Woodrow Wilson Dr, Cancer Institute, Jackson, MS 39213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Drug, Biological
Study Drugs: GEN-1, Carboplatin, Paclitaxel
Study Phase: Phase 1/Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: March 24, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
Enrollment Status: Completed
Publish Date: April 05, 2023
Intervention Type: Drug, Biological
Study Drugs: Vigil Tumor Cells, Atezolizumab
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drugs: Cabozantinib, Pembrolizumab
Study Phase: Phase 2
View 8 Less Clinical Trials

79 Total Publications

MYB/AKT3 axis is a key driver of ovarian cancer growth, aggressiveness, and chemoresistance.
MYB/AKT3 axis is a key driver of ovarian cancer growth, aggressiveness, and chemoresistance.
Journal: Journal of ovarian research
Published: June 26, 2025
Similar Doctors
Distinguished in Melanoma
Dr. James L. Moore
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Melanoma
Dr. James L. Moore
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Medical Foundation Of Central Mississippi Inc

501 Marshall St, Suite 104, 
Jackson, MS 
 (1.2 miles away)
601-969-6404
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Moore is a Gynecologic Oncologist and an Oncologist in Jackson, Mississippi. Dr. Moore is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Vulvar Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Bladder Reconstruction, and Oophorectomy. Dr. Moore is currently accepting new patients.

Distinguished in Melanoma
Dr. Tammy H. Young
Oncology | Hematology
Distinguished in Melanoma
Dr. Tammy H. Young
Oncology | Hematology

Jackson Oncology Associates

1227 N State St, Suite 101, 
Jackson, MS 
 (1.4 miles away)
601-355-2485
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tammy Young is an Oncologist and a Hematologist in Jackson, Mississippi. Dr. Young is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, and Advanced Bronchoscopy. Dr. Young is currently accepting new patients.

Advanced in Melanoma
Dr. Kelly Wilkinson
Hematology | Oncology
Advanced in Melanoma
Dr. Kelly Wilkinson
Hematology | Oncology

State Of Mississippi - University Of Mississippi Medical Center

2500 N State St, 
Jackson, MS 
 (1.4 miles away)
601-898-4404
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kelly Wilkinson is a Hematologist and an Oncologist in Jackson, Mississippi. Dr. Wilkinson is rated as an Advanced provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Familial Colorectal Cancer, Adult Soft Tissue Sarcoma, Melanoma, Colorectal Cancer, and Salpingo-Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rocconi's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile